Ovarian Cancer

    Actionable Target Abnormality Prevalence (%) (1,2) Clinical Experience with Targeted Agent
    PIK3CA Amplification 68 (high grade serous)
    20 (low grade serous)
    20 (endometrioid)
    20 (clear cell)
    MKC-1 (AKT/tubulin inhibitor):
    • Phase 2: SD 37% (3)
    Perifosine (AKT/PI3K inhibitor):
    • Phase 1 (with docetaxel): RR 5%, SD 14% high grade serous only (4)
    Temsirolimus (mTOR inhibitor):
    • Phase 2: RR 9%, SD 24% (5)
    • Phase 2: Trial terminated due to lack of efficacy (6)
    • Phase 2 (frontline with carboplatin and paclitaxel in clear cell): RR 54% in US/Korea and 73%
    Other topics in Targets by Organ Site